Transforming_VBG Growth_NP Factor_NP beta1_JJ Receptor_NP II_NP Is_VBZ Downregulated_JJ by_IN E1A_NP in_IN Adenovirus-Infected_NP Cells_NP Transforming_NP growth_NN factor_NN beta1_NN (_( TGF-beta1_NP )_) signaling_VBG is_VBZ compromised_VBN in_IN many_JJ tumors_NNS ,_, thereby_RB allowing_VBG the_DT tumor_NN to_TO escape_VB the_DT growth-inhibitory_JJ and_CC proapoptotic_JJ activities_NNS of_IN the_DT cytokine_NN ._SENT Human_JJ adenoviruses_NNS interfere_VBP with_IN a_DT number_NN of_IN cellular_JJ pathways_NNS involved_VBN in_IN cell_NN cycle_NN regulation_NN and_CC apoptosis_NN ,_, initially_RB placing_VBG the_DT cell_NN in_IN a_DT "_`` tumor-like_JJ "_'' state_NN by_IN forcing_VBG quiescent_JJ cells_NNS into_IN the_DT cell_NN cycle_NN and_CC also_RB inhibiting_VBG apoptosis_NN ._SENT We_PP report_VBP that_IN adenovirus-infected_JJ cells_NNS resemble_VBP tumor_NN cells_NNS in_IN that_DT TGF-beta1_NP signaling_VBG is_VBZ inhibited_VBN ._SENT The_DT levels_NNS of_IN TGF-beta1_JJ receptor_NN II_NP (_( TbetaRII_NP )_) in_IN adenovirus-infected_JJ cells_NNS were_VBD decreased_VBN ,_, and_CC this_DT decrease_NN was_VBD mapped_VBN ,_, by_IN using_VBG virus_NN mutants_NNS ,_, to_TO the_DT E1A_NP gene_NN and_CC to_TO amino_NN acids_NNS 2_CD to_TO 36_CD and_CC the_DT C-terminal_JJ binding_JJ protein_NN binding_VBG site_NN in_IN the_DT E1A_NP protein_NN ._SENT The_DT decrease_NN in_IN the_DT TbetaRII_NP protein_NN was_VBD accompanied_VBN by_IN a_DT decrease_NN in_IN TbetaRII_NP mRNA_NP ._SENT The_DT decrease_NN in_IN TbetaRII_NP protein_NN levels_NNS in_IN adenovirus-infected_JJ cells_NNS was_VBD greater_JJR than_IN the_DT decrease_NN in_IN TbetaRII_NP mRNA_NP ,_, suggesting_VBG that_DT downregulation_NN of_IN the_DT TbetaRII_NP protein_NN may_MD occur_VB through_IN more_JJR than_IN one_CD mechanism_NN ._SENT Surprisingly_RB in_IN this_DT context_NN ,_, the_DT half-lives_NNS of_IN the_DT TbetaRII_NP protein_NN in_IN infected_JJ and_CC uninfected_JJ cells_NNS were_VBD similar_JJ ._SENT TGF-beta1_NP signaling_VBG was_VBD compromised_VBN in_IN cells_NNS infected_VBN with_IN wild-type_NN adenovirus_NN ,_, as_RB measured_VBN with_IN 3TP-lux_NP ,_, a_DT TGF-beta-sensitive_JJ reporter_NN plasmid_NN expressing_VBG luciferase_NN ._SENT Adenovirus_NN mutants_NNS deficient_JJ in_IN TbetaRII_NP downregulation_NN did_VBD not_RB inhibit_VB TGF-beta1_NP signaling_VBG ._SENT TGF-beta1_JJ pretreatment_NN reduced_VBD the_DT relative_JJ abundance_NN of_IN adenovirus_NN structural_JJ proteins_NNS in_IN infected_JJ cells_NNS ,_, an_DT effect_NN that_WDT was_VBD potentiated_VBN when_WRB cells_NNS were_VBD infected_VBN with_IN mutants_NNS incapable_JJ of_IN modulating_VBG the_DT TGF-beta_NP signaling_VBG pathway_NN ._SENT These_DT results_NNS raise_VBP the_DT possibility_NN that_IN inhibition_NN of_IN TGF-beta_NP signaling_VBG by_IN E1A_NP is_VBZ a_DT means_NN by_IN which_WDT adenovirus_NN counters_VBZ the_DT antiviral_JJ defenses_NNS of_IN the_DT host_NN ._SENT Transforming_VBG growth_NN factor_NN beta1_NN (_( TGF-beta1_NP )_) is_VBZ a_DT prototype_NN member_NN of_IN a_DT family_NN of_IN multifunctional_JJ cytokines_NNS ._SENT Originally_RB discovered_VBN as_IN a_DT fibroblast_NN growth_NN factor_NN ,_, TGF-beta1_NP was_VBD soon_RB found_VBN to_TO play_VB an_DT important_JJ role_NN in_IN a_DT variety_NN of_IN physiological_JJ processes_NNS including_VBG immunoregulation_NN ,_, the_DT cell_NN cycle_NN ,_, apoptosis_NN ,_, and_CC formation_NN of_IN the_DT extracellular_JJ matrix_NN ._SENT In_IN epithelial_JJ cells_NNS ,_, TGF-beta1_NP negatively_RB affects_VBZ the_DT cell_NN cycle_NN primarily_RB through_IN transcriptional_JJ upregulation_NN of_IN cyclin-dependent_JJ kinase_NN inhibitors_NNS ._SENT In_IN the_DT immune_JJ system_NN ,_, TGF-beta1_JJ along_IN with_IN interleukin-10_JJ functions_NNS to_TO control_VB and_CC limit_VB the_DT extent_NN of_IN the_DT adaptive_JJ immune_JJ response_NN ._SENT The_DT signaling_VBG pathways_NNS for_IN all_DT members_NNS of_IN the_DT TGF-beta1_JJ family_NN are_VBP similar_JJ ._SENT Intracellular_JJ signaling_VBG is_VBZ initiated_VBN upon_IN the_DT binding_NN of_IN the_DT active_JJ cytokine_NN to_TO the_DT TGF-beta_NP receptor_NN II_NP (_( TbetaRII_NP )_) homodimer_NN and_CC the_DT assembly_NN of_IN a_DT heterotetrameric_JJ complex_NN consisting_VBG of_IN receptors_NNS I_PP and_CC II_NP ._SENT TbetaRII_NP is_VBZ a_DT ubiquitously_RB expressed_VBN constitutively_RB active_JJ serine/threonine_NN kinase_NN ._SENT Once_IN the_DT heterotetrameric_JJ receptor_NN complex_NN is_VBZ formed_VBN ,_, TbetaRII_NP phosphorylates_NNS TbetaRI_NP and_CC thereby_RB greatly_RB enhances_VBZ TbetaRI_NP serine/threonine_NN kinase_NN activity_NN ._SENT The_DT Smad_NP family_NN of_IN proteins_NNS includes_VBZ secondary_JJ mediators_NNS of_IN TGF-beta_NP signaling_VBG ._SENT Receptor-specific_JJ Smads_NNS that_WDT are_VBP phosphorylated_JJ by_IN activated_VBN TbetaRI_NP associate_NN with_IN Smad_NP 4_CD and_CC other_JJ factors_NNS to_TO form_VB a_DT transcriptionally_RB competent_JJ complex_NN that_WDT enters_VBZ the_DT nucleus_NN and_CC modulates_VBZ gene_NN expression_NN ._SENT The_DT TGF-beta1_JJ signaling_VBG pathway_NN is_VBZ inactivated_VBN in_IN many_JJ tumors_NNS ,_, presumably_RB allowing_VBG the_DT tumors_NNS to_TO escape_VB TGF-beta1-mediated_JJ growth_NN inhibition_NN and_CC apoptosis_NN ._SENT Frequently_RB ,_, inhibition_NN of_IN TGF-beta1_JJ signaling_VBG occurs_VBZ by_IN either_DT abolition_NN of_IN the_DT function_NN of_IN a_DT common_JJ mediator_NN ,_, Smad_NP 4_CD ,_, or_CC by_IN interference_NN with_IN TbetaRII_NP function_NN ._SENT Some_DT of_IN the_DT reported_VBN mechanisms_NNS of_IN TbetaRII_NP downregulation_NN include_VBP inhibition_NN of_IN promoter_NN activity_NN ,_, decrease_NN in_IN mRNA_NN stability_NN ,_, and_CC intracellular_JJ retention_NN ._SENT Human_JJ adenovirus_NN causes_VBZ a_DT number_NN of_IN benign_JJ diseases_NNS and_CC may_MD establish_VB persistency_NN in_IN lymphoid_JJ cells_NNS ._SENT Quiescent_JJ epithelial_JJ cells_NNS are_VBP believed_VBN to_TO be_VB the_DT main_JJ target_NN of_IN acutely_RB replicating_VBG adenovirus_NN in_IN vivo_RB ._SENT Infection_NN is_VBZ divided_VBN into_IN two_CD stages_NNS ,_, early_JJ and_CC late_JJ ._SENT Early_JJ genes_NNS begin_VBP to_TO be_VB expressed_VBN prior_RB to_TO viral_JJ DNA_NN replication_NN and_CC encode_VB proteins_NNS that_WDT usurp_VBP the_DT cell_NN ._SENT Progression_NN into_IN the_DT late_JJ stage_NN of_IN infection_NN and_CC successful_JJ completion_NN of_IN the_DT viral_JJ life_NN cycle_NN require_VBP replication_NN of_IN the_DT viral_JJ DNA_NN genome_NN ._SENT The_DT cellular_JJ DNA_NN synthesis_NN machinery_NN may_MD facilitate_VB viral_JJ genome_NN replication_NN ;_: upon_IN infection_NN ,_, cell_NN cycle_NN perturbations_NNS in_IN quiescent_JJ epithelial_JJ cells_NNS ,_, primarily_RB due_JJ to_TO the_DT adenovirus_NN E1A_NN proteins_NNS ,_, are_VBP observed_VBN ._SENT In_IN addition_NN ,_, the_DT adenovirus_NN genome_NN encodes_VBZ a_DT number_NN of_IN proteins_NNS that_WDT counteract_VBP host_NN cell_NN apoptosis_NN ,_, whether_IN it_PP is_VBZ induced_VBN by_IN unscheduled_JJ cell_NN cycle_NN progression_NN or_CC mediated_VBN by_IN the_DT immune_JJ system_NN ._SENT Because_IN of_IN unscheduled_JJ entry_NN into_IN the_DT cell_NN cycle_NN and_CC protection_NN against_IN apoptosis_NN ,_, adenovirus-infected_JJ cells_NNS are_VBP forced_VBN into_IN a_DT tumor-like_JJ state_NN ._SENT Increased_VBN levels_NNS of_IN active_JJ TGF-beta1_NP are_VBP created_VBN at_IN the_DT site_NN of_IN inflammation_NN through_IN the_DT release_NN of_IN active_JJ cytokines_NNS by_IN a_DT subpopulation_NN of_IN macrophages_NNS and_CC regulatory_JJ T_NN cells_NNS and_CC by_IN local_JJ activation_NN of_IN extracellular_JJ matrix-associated_JJ latent_JJ complexes_NNS ._SENT It_PP seems_VBZ possible_JJ that_IN the_DT growth-inhibitory_JJ and_CC proapoptotic_JJ functions_NNS of_IN TGF-beta1_NP would_MD be_VB both_DT inhibitory_JJ to_TO viral_JJ DNA_NN replication_NN and_CC detrimental_JJ to_TO the_DT survival_NN of_IN infected_JJ epithelial_JJ cells_NNS ._SENT In_IN addition_NN or_CC alternatively_RB ,_, the_DT immunoregulatory_JJ function_NN of_IN TGF-beta1_NP could_MD diminish_VB the_DT antiadenovirus_NN immune_JJ response_NN and_CC accordingly_RB may_MD be_VB beneficial_JJ for_IN in_IN vivo_JJ adenovirus_NN replication_NN and_CC possibly_RB persistence_NN ._SENT Therefore_RB ,_, it_PP is_VBZ reasonable_JJ to_TO consider_VB whether_IN disruption_NN of_IN the_DT TGF-beta1_JJ signaling_VBG pathway_NN might_MD occur_VB in_IN adenovirus-infected_JJ cells_NNS ._SENT Here_RB we_PP report_VBP that_IN adenovirus_NN mediates_VBZ a_DT decrease_NN in_IN TbetaRII_NP protein_NN levels_NNS and_CC that_IN the_DT E1A_NP proteins_NNS are_VBP responsible_JJ for_IN the_DT effect_NN ._SENT This_DT decrease_NN is_VBZ accompanied_VBN by_IN a_DT reduction_NN in_IN steady-state_NN TbetaRII_NP mRNA_NP levels_NNS ._SENT TGF-beta1-mediated_JJ signaling_VBG in_IN infected_JJ cells_NNS is_VBZ inhibited_VBN ;_: adenovirus_NN mutants_NNS that_WDT fail_VBP to_TO downregulate_JJ TbetaRII_NP do_VBP not_RB inhibit_VB TGF-beta1-mediated_JJ signaling_VBG ._SENT Finally_RB ,_, activation_NN of_IN the_DT TGF-beta1_JJ pathway_NN decreases_VBZ the_DT abundance_NN of_IN adenovirus_NN structural_JJ proteins_NNS in_IN infected_JJ cells_NNS ._SENT Cell_NN lines_NNS ._SENT |_SYM Human_NP A549_NP lung_NN adenocarcinoma_NN and_CC human_JJ HepG2_JJ hepatocellular_JJ carcinoma_NN cell_NN lines_NNS were_VBD purchased_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP ._SENT A549_NP cells_NNS were_VBD grown_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP medium_NN (_( DMEM_NP ;_: JRH_NP Biosciences_NP ,_, Lenexa_NP ,_, Kans_NP ._SENT )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN (_( FCS_NN ;_: HyClone_NP ,_, Logan_NP ,_, Utah_NP )_) ._SENT HepG2_JJ cells_NNS were_VBD grown_VBN in_IN DMEM-F12_NP medium_NN supplemented_VBD with_IN 10_CD %_NN FCS_NN ._SENT Adenovirus_NN mutants_NNS ._SENT |_SYM Ad2_NP ,_, Ad5_NP ,_, and_CC rec700_NN were_VBD used_VBN as_IN wild-type_NN controls_NNS ._SENT rec700_NN is_VBZ a_DT recombinant_JJ virus_NN derived_VBN from_IN Ad2_NP and_CC Ad5_NP with_IN an_DT E1A_NP region_NN from_IN Ad5_NP ._SENT E1A.2-36_NP and_CC E1A.81-120_NP are_VBP adenovirus_NN mutants_NNS that_WDT lack_VBP amino_NN acids_NNS 2_CD to_TO 36_CD and_CC 81_CD to_TO 120_CD ,_, respectively_RB ,_, in_IN the_DT E1A_NP proteins_NNS (_( kindly_RB provided_VBN by_IN Elizabeth_NP Moran_NP ,_, Temple_NP University_NP )_) ._SENT pm975_NP and_CC 12Swt_NP express_VBP only_RB the_DT 13S_NP and_CC 12S_NP E1A_NP isoforms_NNS ,_, respectively_RB ._SENT dl808_NN lacks_VBZ the_DT E4_NP region_NN (_( deletion_NN encompasses_VBZ map_NN units_NNS 92.0_CD to_TO 97.1_CD )_) ._SENT dl7001_JJ and_CC dl327_JJ lack_NN the_DT entire_JJ E3_NP region_NN ,_, with_IN the_DT exception_NN of_IN the_DT gene_NN for_IN E3-12.5K_NP present_NN in_IN dl327_JJ ._SENT dl764_NN and_CC dl753_NN ,_, mutants_NNS ,_, derived_VBN from_IN rec700_NN ,_, lack_VBP the_DT RIDbeta_NP and_CC RIDalpha_NP genes_NNS ,_, respectively_RB ._SENT 12S.2-36_JJ and_CC 12S.928_JJ are_VBP 12Swt-based_JJ mutants_NNS with_IN an_DT E1A_NP N_NP terminus_NN deletion_NN and_CC a_DT point_NN mutation_NN ,_, respectively_RB ._SENT dl313_NN expresses_VBZ E1A_NP proteins_NNS lacking_VBG amino_NN acids_NNS 220_CD to_TO 289_CD ._SENT dl312_NN lacks_VBZ the_DT E1A_NP region_NN ._SENT Ad/E3_NP is_VBZ an_DT E1-negative_JJ replication-defective_JJ adenovirus_NN vector_NN expressing_VBG E3_NP proteins_NNS under_IN the_DT control_NN of_IN the_DT cytomegalovirus_NN (_( CMV_NP )_) promoter_NN ._SENT 176-9_CD (_( dC-term_NN )_) is_VBZ a_DT 12S_JJ mutant_NN with_IN a_DT deletion_NN of_IN amino_NN acids_NNS 224_CD to_TO 284_CD in_IN the_DT E1A_NP protein_NN ._SENT dl118_NN is_VBZ an_DT E1B_NP deletion_NN mutant_NN ._SENT Mutants_NNS E1A.2-36_NP ,_, E1A.81-120_NP ,_, pm975_NP ,_, 12Swt_NP ,_, 12S.2-36_JJ ,_, 12S.928_JJ ,_, dl313_JJ ,_, dl312_JJ ,_, and_CC dl118_NN are_VBP all_RB in_IN a_DT dl309_JJ genetic_JJ background_NN ._SENT dl309_NN is_VBZ an_DT Ad5_NP mutant_NN that_WDT lacks_VBZ the_DT genes_NNS for_IN the_DT E3_NP RIDalpha_NP ,_, RIDbeta_NP ,_, and_CC 14.7K_NN proteins_NNS ._SENT Antibodies_NNS and_CC reagents_NNS ._SENT |_SYM Rabbit_NP anti-TbetaRII_NP antibodies_NNS used_VBN for_IN Western_JJ analysis_NN were_VBD purchased_VBN from_IN Santa_NP Cruz_NP Biotechnology_NP (_( catalog_NN numbers_NNS sc-400_NN and_CC sc-220_NN ;_: Santa_NP Cruz_NP ,_, Calif._NP )_) ._SENT Affinity-purified_JJ goat_NN anti-TbetaRII_NNS raised_VBN against_IN an_DT extracellular_JJ receptor_NN domain_NN was_VBD purchased_VBN from_IN R&D_NP Systems_NP (_( catalog_NN number_NN AF-241-NA_NP ;_: Minneapolis_NP ,_, Minn._NP )_) and_CC used_VBN for_IN immunoprecipitations_NNS ._SENT A_DT rabbit_NN anti-Ad5_NN antibody_NN was_VBD purchased_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP ._SENT The_DT anti-phospho-Smad_NN 2_CD antibody_NN was_VBD from_IN Upstate_NP Biotechnology_NP (_( Charlottesville_NP ,_, Va._NP )_) ._SENT Recombinant_JJ human_JJ TGF-beta1_NN was_VBD purchased_VBN from_IN R&D_NP Systems_NPS ;_: it_PP was_VBD reconstituted_VBN and_CC stored_VBN in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Western_JJ analysis_NN ._SENT |_SYM HepG2_NP or_CC A549_NP cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN phosphate-buffered_JJ saline_NN and_CC lysed_VBN on_IN ice_NN in_IN radioimmunoprecipitation_NN assay_NN buffer_NN (_( 50_CD mM_NP Tris_NP [_SYM pH_NN 8.0_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 1_CD %_NN Triton_NP X-100_NP ,_, 0.5_CD %_NN sodium_NN deoxycholate_NN ,_, 0.1_CD %_NN sodium_NN dodecyl_JJ sulfate_NN [_SYM SDS_NP ]_SYM ,_, 1_CD mM_NP EDTA_NP ,_, 1_CD mM_NP NaF_NP )_) for_IN 30_CD min_NN ._SENT Aspirated_VBN buffer_NN was_VBD centrifuged_VBN at_IN 12,000_CD rpm_NN in_IN an_DT Eppendorf_NP centrifuge_NN (_( model_NN 5415C_NN )_) for_IN 10_CD min_NN ,_, and_CC the_DT protein_NN concentration_NN of_IN the_DT supernatant_JJ was_VBD measured_VBN by_IN the_DT Bio-RadDC_NP protein_NN assay_NN (_( Bio-Rad_NP Laboratories_NP ,_, Hercules_NP ,_, Calif._NP )_) ._SENT Equal_JJ protein_NN amounts_NNS of_IN 50_CD (_( TbetaRII_NP )_) or_CC 30_CD mug_NN (_( adenovirus_NN late_JJ proteins_NNS )_) were_VBD loaded_VBN into_IN each_DT lane_NN of_IN the_DT SDS-8_NP %_NN polyacrylamide_NN gel_NN electrophoresis_NN (_( PAGE_NP )_) gel_NN ._SENT Proteins_NNS were_VBD transferred_VBN to_TO a_DT polyvinylidene_JJ difluoride_NN membrane_NN (_( Immobilon-P_NP ;_: Millipore_NP ,_, Bedford_NP ,_, Mass._NP )_) and_CC incubated_VBN with_IN a_DT combination_NN of_IN anti-TbetaRII_NP antibodies_NNS (_( 1:300_CD dilution_NN each_DT )_) or_CC the_DT anti-Ad5_JJ antibody_NN (_( 1:1,600_CD dilution_NN )_) ._SENT Following_VBG application_NN of_IN the_DT secondary_JJ horseradish_NN peroxidase-conjugated_JJ antibody_NN and_CC subsequent_JJ washes_VBZ ,_, a_DT signal_NN was_VBD generated_VBN with_IN a_DT commercial_JJ chemiluminescence_NN substrate_NN (_( LumiGLO_NP ;_: KPL_NP ,_, Gaithersburg_NP ,_, Md._NP )_) ._SENT The_DT signal_NN was_VBD detected_VBN by_IN autoradiography_NN and_CC quantified_VBN by_IN densitometry_NN using_VBG FluorChem_NP software_NN (_( Alpha_NP Innotech_NP Corporation_NP ,_, San_NP Leandro_NP ,_, Calif._NP )_) ._SENT Analysis_NN of_IN late_JJ protein_NN synthesis_NN ._SENT |_SYM A549_NP cells_NNS were_VBD maintained_VBN under_IN 10_CD or_CC 0.2_CD %_NN FCS_NN or_CC 0.2_CD %_NN FCS_NN plus_CC 5_CD ng_NNS of_IN TGF-beta1/ml_NP for_IN 3_CD days_NNS prior_RB to_TO infection_NN and_CC throughout_IN the_DT infection_NN ._SENT During_IN 3_CD days_NNS of_IN pretreatment_NN ,_, medium_NN was_VBD refreshed_VBN once_RB to_TO sustain_VB the_DT activity_NN of_IN the_DT cytokine_NN ._SENT Fresh_JJ medium_NN was_VBD also_RB supplied_VBN at_IN the_DT beginning_NN of_IN the_DT infection_NN ._SENT RPA_NP ._SENT |_SYM HepG2_NP cells_NNS were_VBD mock_JJ infected_JJ or_CC infected_JJ with_IN adenovirus_NN mutants_NNS and_CC maintained_VBN in_IN the_DT presence_NN of_IN AraC_NP ._SENT Total_NP RNA_NP was_VBD isolated_VBN from_IN infected_JJ and_CC mock-infected_JJ HepG2_JJ cells_NNS with_IN TRIzol_NP reagent_NN (_( Invitrogen_NP ,_, Carlsbad_NP ,_, Calif._NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Radioactively_RB labeled_VBN RNA_NP antisense_NN probes_NNS were_VBD generated_VBN by_IN the_DT Riboprobe_NP Combination_NP System_NP Sp6/T7_NP (_( Promega_NP ,_, Madison_NP ,_, Wis._NP )_) ._SENT The_DT TbetaRII_NP probe_NN was_VBD synthesized_VBN with_IN T7_JJ polymerase_NN from_IN a_DT pBluescript_JJ TbetaRII_NP probe_NN plasmid_NN linearized_VBN with_IN HindIII_NP ._SENT To_TO generate_VB the_DT pBluescript_JJ TbetaRII_NP probe_NN ,_, a_DT HindIII-PstI_NP TbetaRII_NP fragment_NN recovered_VBD from_IN the_DT mycTbetaRII_NP plasmid_NP (_( kindly_RB provided_VBN by_IN Yoav_NP Henis_NP ,_, Tel_NP Aviv_NP University_NP )_) was_VBD cloned_VBN into_IN the_DT pBluescript_NN (_( -_: )_) multiple_JJ cloning_VBG site_NN ._SENT The_DT GAPDH_NP (_( glyceraldehyde-3-phosphate_NN dehydrogenase_NN )_) probe_NN was_VBD synthesized_VBN with_IN Sp6_NP polymerase_NN from_IN an_DT XbaI-linearized_JJ template_NN (_( kindly_RB provided_VBN by_IN Rob_NP Fleming_NP ,_, Saint_NP Louis_NP University_NP )_) ._SENT Thirty_CD (_( TbetaRII_NP )_) or_CC 6_CD (_( GAPDH_NP )_) mug_NN of_IN total_JJ RNA_NP was_VBD hybridized_VBN to_TO the_DT freshly_RB made_VBN radioactively_RB labeled_VBN probes_NNS and_CC processed_VBN with_IN a_DT commercially_RB available_JJ RNase_NP protection_NN assay_NN (_( RPA_NP )_) kit_NN (_( RPAIII_NP ;_: Ambion_NP ,_, Dallas_NP ,_, Tex._NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Immunoprecipitations_NNS ._SENT |_SYM A549_NP cells_NNS were_VBD mock_JJ infected_JJ or_CC infected_JJ with_IN rec700_NN at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 50_CD PFU/cell_NP and_CC maintained_VBN in_IN the_DT presence_NN of_IN 20_CD mug_NN of_IN AraC/ml_NP ._SENT At_IN 18.5_CD h_NN postinfection_NN (_( p.i._NP )_) ,_, cells_NNS were_VBD washed_VBN and_CC incubated_VBN with_IN DMEM_NP lacking_JJ cysteine_NN and_CC methionine_NN for_IN 30_CD min_NN ._SENT At_IN 19_CD h_NN p.i._NN ,_, the_DT preincubation_NN medium_NN was_VBD changed_VBN to_TO fresh_JJ cysteine-_NN and_CC methionine-negative_JJ DMEM_NN supplemented_VBN with_IN 100_CD muCi_NNS of_IN a_DT [_SYM 35S]methionine-cysteine_JJ mixture_NN (_( EasyTag_NP Express_NP protein_NN labeling_VBG mixture_NN ;_: Perkin-Elmer_NP ,_, Boston_NP ,_, Mass.)/ml_NP ._SENT After_IN 15_CD min_NN of_IN incubation_NN in_IN radioactive_JJ medium_NN ,_, cells_NNS were_VBD either_RB immediately_RB placed_VBN on_IN ice_NN (_( 0-h_NN chase_NN )_) or_CC washed_VBN three_CD times_NNS with_IN prewarmed_JJ cold_JJ DMEM_NN and_CC incubated_VBN in_IN DMEM_NP containing_VBG 10_CD %_NN FCS_NN for_IN the_DT time_NN period_NN shown_VBN in_IN Fig._NN ._SENT At_IN the_DT end_NN of_IN a_DT chase_JJ period_NN ,_, the_DT cells_NNS were_VBD placed_VBN on_IN ice_NN ,_, washed_VBD four_CD times_NNS with_IN ice-cold_JJ phosphate-buffered_JJ saline_NN ,_, and_CC scraped_VBD into_IN 100_CD mul_NN of_IN 0.5_CD %_NN NP-40_JJ lysis_NN buffer_NN (_( 20_CD mM_NP sodium_NN phosphate_NN ,_, 250_CD mM_NP NaCl_NP ,_, 30_CD mM_NP sodium_NN pyrophosphate_NN ,_, 5_CD mM_NP EDTA_NP ,_, 10_CD mM_NP NaF_NP )_) ._SENT Cell_NN lysates_NNS were_VBD normalized_VBN to_TO the_DT amount_NN of_IN protein_NN in_IN the_DT lysate_NN and_CC combined_VBN with_IN 0.25_CD mug_NN of_IN the_DT antibody_NN and_CC 20_CD mul_NN of_IN 50_CD %_NN protein_NN G-agarose_NP (_( Roche_NP ,_, Indianapolis_NP ,_, Ind._NP )_) ._SENT Following_VBG overnight_JJ incubation_NN ,_, the_DT agarose_JJ beads_NNS were_VBD washed_VBN with_IN 0.5_CD %_NN SDS_NP lysis_NN buffer_NN ;_: immunoprecipitated_JJ proteins_NNS were_VBD dissociated_VBN from_IN the_DT agarose_NN in_IN 2x_NP Laemmli_NP buffer_NN and_CC separated_VBN on_IN SDS-8_NP %_NN PAGE_NN gels_NNS ._SENT Gels_NNS were_VBD dried_VBN ,_, and_CC the_DT signal_NN was_VBD visualized_VBN by_IN autoradiography_NN and_CC phosphorimaging_NN with_IN a_DT STORM_NP phosphorimager_NN ,_, with_IN subsequent_JJ quantitation_NN by_IN ImageQuant_NP ,_, version_NN 4.0_CD ,_, software_NN ._SENT Luciferase_NN assay_NN ._SENT |_SYM HepG2_NP cells_NNS seeded_VBN in_IN 24-well_JJ dishes_NNS were_VBD transfected_VBN with_IN 0.5_CD mug_NN of_IN 3TP-lux_JJ (_( kindly_RB provided_VBN by_IN J._NP Massague_NP ,_, Sloan-Kettering_NP Institute_NP )_) and_CC 0.3_CD mug_NN of_IN pCMV-beta_NP Gal_NP plasmid_NP ._SENT At_IN 6_CD h_NN posttransfection_NN ,_, HepG2_NP cells_NNS were_VBD mock_JJ infected_JJ or_CC infected_JJ with_IN rec700_NN at_IN 50_CD PFU/cell_NP ._SENT Infections_NNS were_VBD maintained_VBN in_IN the_DT presence_NN of_IN freshly_RB supplied_VBN AraC_NP at_IN 20_CD mug/ml_NN ._SENT At_IN 12_CD h_NN p.i._NN ,_, medium_NN was_VBD replaced_VBN with_IN serum-free_JJ medium_NN containing_VBG 5_CD ng_NNS of_IN human_JJ recombinant_JJ TGF-beta1_NP (_( R&D_NP Systems)/ml_NP ._SENT At_IN 26_CD h_NN p.i._NN ,_, cells_NNS were_VBD lysed_VBN ,_, and_CC luciferase_NN activity_NN was_VBD measured_VBN with_IN a_DT luminometer_NN by_IN using_VBG the_DT luciferase_NN assay_NN system_NN (_( Promega_NP )_) ._SENT To_TO determine_VB beta-Gal_JJ activity_NN ,_, the_DT same_JJ volume_NN of_IN cell_NN lysate_NNS was_VBD incubated_VBN in_IN assay_NN buffer_NN (_( 200_CD mM_NP sodium_NN phosphate_NN [_SYM pH_NN 7.3_CD ]_SYM ,_, 2_CD mM_NP MgCl2_NP ,_, 100_CD mM_NP beta-mercaptoethanol_NN ,_, 1.33_CD mg_NN of_IN o-nitrophenyl-beta-d-galactopyranoside_NP [_SYM ONPG]/ml_NN )_) and_CC measured_VBN on_IN a_DT spectrophotometer_NN at_IN 405_CD nm_NN ._SENT In_IN place_NN of_IN infection_NN ,_, in_IN some_DT experiments_NNS cells_NNS were_VBD cotransfected_VBN with_IN 0.5_CD mug_NN of_IN either_DT 13S_NP E1A_NP or_CC 12S_NP E1A_NP plasmids_NNS (_( kindly_RB provided_VBN by_IN G._NP Chinnadurai_NP ,_, Saint_NP Louis_NP University_NP )_) ._SENT TbetaRII_NP is_VBZ downregulated_JJ in_IN the_DT course_NN of_IN adenovirus_NN infection_NN ._SENT |_SYM Figure_NN illustrates_VBZ TbetaRII_NP protein_NN levels_NNS observed_VBN in_IN human_JJ A549_NP cells_NNS infected_VBN with_IN rec700_NN ,_, an_DT Ad5-Ad2-Ad5_NP recombinant_JJ that_IN functions_NNS as_IN a_DT wild-type_NN adenovirus_NN ._SENT Two_CD forms_NNS of_IN TbetaRII_NP are_VBP shown_VBN :_: the_DT mature_JJ form_NN of_IN the_DT receptor_NN and_CC the_DT short-lived_JJ TbetaRII_NP precursor_NN ._SENT (_( This_DT precursor_NN has_VBZ been_VBN shown_VBN to_TO be_VB sensitive_JJ to_TO endoglycosidase_NN H_NN digestion_NN in_IN vitro_NN in_IN extracts_VBZ obtained_VBN from_IN Mv1Lu_NP cells_NNS )_) ._SENT TbetaRII_NP levels_NNS in_IN adenovirus-infected_JJ cells_NNS were_VBD significantly_RB decreased_VBN ;_: in_IN multiple_JJ experiments_NNS ,_, only_RB 5_CD to_TO 20_CD %_NN of_IN TbetaRII_NP proteins_NNS remained_VBD at_IN 19_CD h_NN p.i._NP Blocking_NP DNA_NP synthesis_NN with_IN AraC_NP maintains_VBZ adenovirus_NN infection_NN in_IN the_DT early_JJ stage_NN ._SENT As_IN shown_VBN in_IN Fig._NN (_( lane_NN 3_CD )_) ,_, TbetaRII_NP levels_NNS in_IN AraC-treated_JJ infected_JJ cells_NNS were_VBD decreased_VBN ,_, indicating_VBG that_IN the_DT decrease_NN is_VBZ mediated_VBN by_IN an_DT adenovirus_NN early_JJ protein_NN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN with_IN HepG2_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT A_DT time_NN course_NN of_IN TbetaRII_NP downregulation_NN in_IN adenovirus-infected_JJ cells_NNS is_VBZ presented_VBN in_IN Fig._NN ._SENT Only_RB the_DT mature_JJ form_NN of_IN TbetaRII_NP is_VBZ shown_VBN ._SENT The_DT decrease_NN in_IN TbetaRII_NP levels_NNS first_RB became_VBD evident_JJ between_IN 13_CD and_CC 15_CD h_NN p.i._NP E1A_NP is_VBZ responsible_JJ for_IN the_DT decrease_NN in_IN TbetaRII_NP protein_NN levels_NNS in_IN adenovirus-infected_JJ cells_NNS ._SENT |_SYM A_DT set_NN of_IN adenovirus_NN mutants_NNS was_VBD used_VBN to_TO map_VB TbetaRII_NP downregulation_NN to_TO an_DT early_JJ protein_NN function_NN ._SENT Wild-type_NP rec700_NP ,_, Ad2_NP ,_, and_CC Ad5_NP were_VBD highly_RB effective_JJ in_IN decreasing_VBG TbetaRII_NP levels_NNS (_( Fig._NN ,_, lanes_NNS b_NN ,_, f_LS ,_, and_CC g_NN )_) ._SENT Virus_NN mutants_NNS lacking_VBG most_JJS of_IN the_DT E4_NP (_( dl808_NN )_) or_CC E1B_NP (_( dl118_NN )_) region_NN were_VBD similar_JJ to_TO wild-type_NN virus_NN in_IN clearing_VBG TbetaRII_NP (_( Fig._NN ,_, lane_JJ e_NN ,_, and_CC C_NP ,_, lane_NN c_NN )_) ._SENT Thus_RB ,_, the_DT E1B_NP and_CC E4_NP regions_NNS are_VBP not_RB required_VBN to_TO downregulate_VB TbetaRII_NP ._SENT Several_JJ mutants_NNS with_IN lesions_NNS in_IN the_DT E3_NP region_NN were_VBD examined_VBN inasmuch_RB as_IN E3_NP proteins_NNS downregulate_VBP a_DT number_NN of_IN cell_NN surface_NN receptors_NNS ,_, including_VBG epidermal_JJ growth_NN factor_NN receptor_NN ,_, Fas_NP ,_, and_CC TRAIL_NP receptors_NNS 1_CD and_CC 2_CD ._SENT Somewhat_RB surprisingly_RB ,_, deletion_NN of_IN all_RB or_CC nearly_RB all_RB of_IN the_DT E3_NP region_NN (_( dl7001_JJ and_CC dl327_JJ ;_: Fig._NN ,_, lanes_NNS c_SYM and_CC d_LS )_) or_CC deletion_NN of_IN the_DT gene_NN for_IN RIDalpha_NP (_( dl753_NP ;_: Fig._NN ,_, lane_JJ b_NN )_) or_CC RIDbeta_NP (_( dl764_NP ;_: Fig._NN ,_, lane_NN i_NP )_) did_VBD not_RB affect_VB TbetaRII_NP downregulation_NN ._SENT In_IN addition_NN ,_, expression_NN of_IN all_DT E3_NP genes_NNS from_IN the_DT deleted_VBN E1_JJ region_NN of_IN replication-defective_JJ adenovirus_NN (_( Ad/E3_NP )_) failed_VBD to_TO remove_VB TbetaRII_NP at_IN 2_CD days_NNS p.i._JJ (_( Fig._NN ,_, lane_JJ g_NN )_) ._SENT These_DT results_NNS indicate_VBP that_IN E3_NP proteins_NNS are_VBP not_RB required_VBN to_TO decrease_VB TbetaRII_NP levels_NNS ._SENT Given_VBN that_DT downregulation_NN of_IN TbetaRII_NP is_VBZ an_DT early_JJ function_NN and_CC that_IN the_DT early_JJ E1B_NP ,_, E3_NP ,_, and_CC E4_NP regions_NNS are_VBP not_RB required_VBN to_TO mediate_VB the_DT decrease_NN in_IN TbetaRII_NP ,_, the_DT immediate-early_JJ E1A_NP region_NN was_VBD examined_VBN ._SENT Mutant_JJ dl312_NN lacks_VBZ most_JJS of_IN the_DT E1A_NP region_NN ;_: TbetaRII_NP levels_NNS in_IN cells_NNS infected_VBN with_IN dl312_NN were_VBD not_RB decreased_VBN (_( Fig._NN ,_, lane_JJ e_NN )_) ,_, establishing_VBG that_IN E1A_NP expression_NN is_VBZ required_VBN for_IN TbetaRII_NP downregulation_NN ._SENT There_EX are_VBP two_CD interpretations_NNS of_IN this_DT result_NN :_: first_RB ,_, the_DT E1A_NP protein_NN itself_PP could_MD be_VB responsible_JJ for_IN TbetaRII_NP downregulation_NN ;_: second_JJ ,_, considering_VBG that_IN E1A_NP is_VBZ required_VBN for_IN efficient_JJ induction_NN of_IN adenovirus_NN genes_NNS ,_, an_DT E1A-inducible_JJ viral_JJ protein(s)_NN could_MD be_VB responsible_JJ ._SENT We_PP favor_VBP the_DT first_JJ interpretation_NN because_IN under_IN the_DT conditions_NNS of_IN the_DT experiment_NN ,_, namely_RB ,_, high_JJ multiplicity_NN of_IN infection_NN (_( 50_CD PFU/cell_NP )_) and_CC a_DT long_JJ period_NN p.i._NN (_( 48_CD h_NN )_) ,_, it_PP is_VBZ known_VBN that_IN adenovirus_NN early_JJ genes_NNS are_VBP expressed_VBN in_IN an_DT E1A-independent_JJ manner_NN ._SENT The_DT E1A_NP gene_NN is_VBZ expressed_VBN as_IN two_CD major_NN alternatively_RB spliced_VBD 13S_JJ and_CC 12S_JJ mRNAs_NNS ,_, which_WDT encode_VBP proteins_NNS of_IN 289_CD (_( 289R_NN )_) and_CC 243_CD (_( 243R_NP )_) amino_NN acids_NNS ,_, respectively_RB ._SENT A_DT mutant_NN expressing_VBG either_CC the_DT 13S_JJ or_CC 12S_JJ isoform_NN of_IN E1A_NP (_( pm975_NP or_CC 12Swt_NP ,_, respectively_RB )_) was_VBD effective_JJ in_IN downregulating_VBG TbetaRII_NP (_( Fig._NN ,_, lane_JJ h_NN ,_, and_CC C_NP ,_, lane_NN e_NN )_) (_( pm975_NN was_VBD not_RB quite_RB as_RB effective_JJ as_IN the_DT wild_JJ type_NN )_) ._SENT The_DT finding_NN that_IN 12S_NP E1A_NP alone_RB is_VBZ functional_JJ excludes_VBZ a_DT rigorous_JJ requirement_NN for_IN the_DT E1A_NP CR3_NP domain_NN ,_, which_WDT is_VBZ present_JJ in_IN the_DT 289R_JJ protein_NN but_CC absent_JJ from_IN the_DT 243R_JJ protein_NN ,_, in_IN suppressing_VBG TbetaRII_NP levels_NNS ._SENT Interestingly_RB ,_, when_WRB adenoviruses_NNS with_IN mutations_NNS in_IN E1A_NP were_VBD examined_VBN ,_, a_DT defect_NN in_IN TbetaRII_NP downregulation_NN was_VBD observed_VBN ._SENT Mutant_JJ dl313_NN was_VBD mostly_RB defective_JJ in_IN clearing_VBG TbetaRII_NP (_( Fig._NN ,_, lane_JJ d_NN )_) ._SENT Mutant_JJ dl313_NN expresses_VBZ E1A_NP proteins_NNS that_WDT are_VBP truncated_VBN at_IN their_PP$ C_NP termini_NNS (_( deletion_NN of_IN amino_NN acids_NNS 220_CD to_TO 289_CD )_) ,_, suggesting_VBG that_IN the_DT C-terminal_JJ portion_NN of_IN the_DT E1A_NP proteins_NNS is_VBZ required_VBN for_IN downregulation_NN of_IN TbetaRII_NP ._SENT In_IN accord_NN with_IN this_DT suggestion_NN ,_, a_DT phenotype_NN similar_JJ to_TO that_DT of_IN dl313_NN was_VBD observed_VBN in_IN a_DT 12Swt_JJ mutant_NN (_( dC-term_NN )_) with_IN an_DT E1A_NN whose_WP$ C_NP terminus_NN lacked_VBD amino_NN acids_NNS 224_CD through_IN 284_CD (_( including_VBG the_DT C-terminal_JJ binding_JJ protein_NN [_SYM CtBP_NP ]_SYM binding_JJ site_NN )_) (_( Fig._NN ,_, lane_JJ f_NN )_) ._SENT (_( Mutant_JJ dl313_NN also_RB lacks_VBZ the_DT E1B_NP region_NN ,_, but_CC given_VBN that_IN the_DT E1B_NP mutant_JJ dl118_NN was_VBD not_RB defective_JJ in_IN downregulating_VBG TbetaRII_NP [_SYM Fig._NN ,_, lane_JJ c_NN ]_SYM ,_, we_PP presume_VBP that_IN the_DT defect_NN is_VBZ due_JJ to_TO the_DT deletion_NN in_IN the_DT C-terminal_JJ region_NN of_IN E1A_NP ._SENT )_) In_IN addition_NN to_TO the_DT C-terminal_JJ region_NN of_IN E1A_NP ,_, the_DT N-terminal_JJ region_NN is_VBZ also_RB important_JJ because_IN a_DT 12Swt_JJ mutant_NN (_( 12S.2-36_JJ )_) with_IN an_DT E1A_NP lacking_JJ amino_NN acids_NNS 2_CD to_TO 36_CD was_VBD completely_RB incapable_JJ of_IN TbetaRII_NP downregulation_NN (_( Fig._NN ,_, lane_JJ c_NN )_) ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT absence_NN of_IN the_DT pRB_NN binding_VBG site_NN in_IN another_DT 12Swt_JJ mutant_NN (_( 12S.928_NP )_) had_VBD no_DT effect_NN on_IN the_DT efficiency_NN of_IN TbetaRII_NP downregulation_NN (_( Fig._NN ,_, lane_JJ d_NN )_) ._SENT The_DT importance_NN of_IN the_DT N-terminal_NP E1A_NP domain_NN for_IN effective_JJ TbetaRII_NP downregulation_NN was_VBD further_RBR confirmed_VBN by_IN examining_VBG TbetaRII_NP levels_NNS in_IN cells_NNS infected_VBN with_IN E1A_NP mutants_NNS that_WDT express_VBP both_CC the_DT 13S_JJ and_CC 12S_JJ forms_NNS of_IN E1A_NP ._SENT Mutants_NNS E1A.2-36_NP and_CC E1A.81-120_NP (_( derived_VBN from_IN dl309_NN )_) express_VBP mutant_JJ E1A_NP proteins_NNS lacking_VBG amino_NN acids_NNS 2_CD to_TO 36_CD and_CC 81_CD to_TO 120_CD ,_, respectively_RB ._SENT As_IN expected_VBN ,_, the_DT E1A.2-36_NP mutant_NN was_VBD unable_JJ to_TO downregulate_VB TbetaRII_NP ,_, whereas_IN E1A.81-120_NP was_VBD as_RB efficient_JJ as_IN the_DT parent_NN virus_NN ._SENT All_DT infections_NNS were_VBD monitored_VBN in_IN parallel_NN for_IN expression_NN of_IN E1A_NP and_CC the_DT E2_NP DNA_NP binding_JJ protein_NN (_( DBP_NP )_) by_IN immunofluorescence_NN ;_: typically_RB ,_, 90_CD to_TO 95_CD %_NN of_IN cells_NNS stained_VBD positive_JJ for_IN E1A_NP when_WRB applicable_JJ ,_, and_CC 60_CD to_TO 70_CD %_NN were_VBD DBP_NP positive_NN ,_, with_IN a_DT homogenous_JJ pattern_NN of_IN staining_VBG in_IN cells_NNS incubated_VBN with_IN AraC_NP (_( data_NN not_RB shown_VBN )_) ._SENT We_PP conclude_VBP that_IN the_DT 13S_JJ (_( 289R_JJ )_) and_CC 12S_JJ (_( 243R_JJ )_) forms_NNS of_IN E1A_NP force_NN downregulation_NN of_IN TbetaRII_NP protein_NN ,_, that_IN the_DT N-terminal_JJ (_( amino_NN acids_NNS 2_CD to_TO 36_CD )_) and_CC C-terminal_NP (_( amino_NN acids_NNS 224_CD to_TO 284_CD )_) regions_NNS of_IN the_DT E1A_NP proteins_NNS are_VBP required_VBN for_IN TbetaRII_NP downregulation_NN ,_, and_CC that_IN the_DT pRb-binding_JJ region_NN of_IN the_DT E1A_NP protein_NN is_VBZ not_RB required_VBN ._SENT Adenovirus_NN 's_POS ability_NN to_TO decrease_VB TbetaRII_NP protein_NN levels_NNS correlates_NNS with_IN its_PP$ ability_NN to_TO downregulate_VB TbetaRII_NP mRNA_NP ._SENT |_SYM As_IN a_DT means_VBZ to_TO examine_VB whether_IN the_DT decrease_NN in_IN TbetaRII_NP protein_NN levels_NNS was_VBD due_JJ to_TO a_DT decrease_NN in_IN TbetaRII_NP mRNA_NP levels_NNS ,_, an_DT RNase_NP protection_NN assay_NN was_VBD employed_VBN to_TO determine_VB TbetaRII_NP mRNA_NN levels_NNS in_IN mock-infected_JJ cells_NNS and_CC cells_NNS infected_VBN with_IN a_DT limited_JJ set_NN of_IN E1A_NP mutants_NNS ._SENT The_DT densities_NNS of_IN the_DT RNase-protected_JJ fragments_NNS were_VBD analyzed_VBN with_IN FluorChem_NP software_NN (_( Alpha_NP Innotech_NP Corporation_NP )_) and_CC are_VBP presented_VBN in_IN the_DT graphs_NNS under_IN the_DT corresponding_JJ autoradiography_NN data_NNS (_( Fig._NN and_CC B_NN )_) ._SENT The_DT density_NN of_IN each_DT TbetaRII_NP fragment_NN was_VBD normalized_VBN against_IN the_DT density_NN of_IN the_DT corresponding_JJ GAPDH_NP signal_NN ._SENT Figure_NN shows_VBZ that_IN the_DT decrease_NN in_IN TbetaRII_NP mRNA_NP (_( seen_VBN as_IN two_CD RNase-protected_JJ bands_NNS )_) was_VBD most_RBS apparent_JJ in_IN rec700-infected_JJ cells_NNS (_( compare_VB lane_JJ e_NN with_IN lane_JJ d_NN )_) (_( 2.7-_CD and_CC 2.4-fold_JJ decreases_NNS in_IN the_DT TbetaRII_NP signal_NN compared_VBN to_TO signals_NNS for_IN mock_JJ infection_NN and_CC infection_NN with_IN E1A-negative_JJ mutant_JJ dl312_NN ,_, respectively_RB )_) ._SENT TbetaRII_NP mRNA_NP levels_NNS were_VBD also_RB decreased_VBN in_IN cells_NNS infected_VBN with_IN a_DT mutant_NN expressing_VBG only_RB the_DT 13S_JJ or_CC 12S_JJ isoform_NN of_IN E1A_NP (_( pm975_NP or_CC 12Swt_NP ,_, respectively_RB ;_: lanes_NNS f_NN and_CC g_NN )_) ,_, but_CC the_DT decrease_NN in_IN TbetaRII_NP mRNA_NP due_JJ to_TO these_DT two_CD mutants_NNS was_VBD consistently_RB less_JJR than_IN that_DT due_JJ to_TO the_DT wild-type_NN adenovirus_NN (_( Fig._NN and_CC B_NN )_) ._SENT TbetaRII_NP mRNA_NP levels_NNS in_IN cells_NNS infected_VBN with_IN dl312_JJ (_( Fig._NN ,_, lane_JJ h_NN )_) were_VBD similar_JJ to_TO those_DT in_IN mock-infected_JJ cells_NNS (_( lane_JJ d_NN )_) ._SENT Under_IN the_DT conditions_NNS of_IN infection_NN used_VBN (_( 50_CD PFU/cell_NP ,_, 43_CD h_NN p.i._NN )_) ,_, early_JJ and_CC late_JJ virus_NN genes_NNS are_VBP expressed_VBN by_IN dl312_JJ (_( ;_: our_PP$ unpublished_JJ observations_NNS )_) ._SENT Therefore_RB ,_, it_PP is_VBZ likely_JJ that_IN TbetaRII_NP mRNAs_NNS are_VBP not_RB downregulated_JJ by_IN dl312_NN because_IN it_PP does_VBZ not_RB make_VB the_DT E1A_NP protein_NN although_IN it_PP makes_VBZ other_JJ adenovirus_NN proteins_NNS ._SENT Figure_NN illustrates_VBZ the_DT TbetaRII_NP mRNA_NN levels_NNS with_IN two_CD 12Swt-based_JJ mutants_NNS ._SENT Mutant_JJ 12S.928_JJ (_( Fig._NN ,_, lane_JJ g_NN )_) ,_, which_WDT is_VBZ defective_JJ in_IN binding_JJ pRB_NN ,_, decreased_VBD TbetaRII_NP mRNA_NP levels_NNS similarly_RB to_TO the_DT parent_NN virus_NN (_( 12Swt_NP ;_: Fig._NN ,_, lane_JJ e_NN )_) ,_, whereas_IN 12S.2-36_JJ had_VBD no_DT effect_NN on_IN TbetaRII_NP mRNA_NP levels_NNS (_( Fig._NN ,_, lane_JJ f_NN )_) ._SENT GAPDH_NP mRNA_NP ,_, which_WDT was_VBD used_VBN as_IN a_DT control_NN ,_, was_VBD not_RB affected_VBN by_IN these_DT viruses_NNS (_( Fig._NN and_CC B_NN ,_, lanes_NNS i_NP to_TO m_NN )_) ._SENT Interestingly_RB ,_, a_DT DeltaCtBP_NP mutant_NN that_WDT is_VBZ partially_RB defective_JJ in_IN decreasing_VBG TbetaRII_NP protein_NN levels_NNS (_( Fig._NN ,_, lane_JJ f_NN )_) was_VBD as_RB efficient_JJ as_IN the_DT parent_NN 12Swt_JJ virus_NN in_IN decreasing_VBG the_DT corresponding_JJ mRNA_NN levels_NNS (_( Fig._NN ,_, compare_VBP lanes_NNS c_SYM and_CC d_LS )_) ,_, suggesting_VBG that_IN E1A_NP second-exon_NN functions_NNS ,_, including_VBG encoding_VBG the_DT CtBP_NP binding_JJ domain_NN ,_, are_VBP dispensable_JJ for_IN the_DT TbetaRII_NP mRNA_NN decrease_NN in_IN infected_JJ cells_NNS ._SENT In_IN conclusion_NN ,_, in_IN accord_NN with_IN the_DT results_NNS of_IN the_DT previous_JJ section_NN ,_, E1A_NP proteins_NNS ,_, and_CC particularly_RB the_DT N-terminal_JJ amino_NN acids_NNS of_IN E1A_NP ,_, decrease_NN TbetaRII_NP mRNA_NP in_IN adenovirus-infected_JJ cells_NNS ._SENT Dynamics_NNS of_IN the_DT TbetaRII_NP protein_NN as_IN determined_VBN by_IN pulse-chase_NN analysis_NN are_VBP affected_VBN in_IN adenovirus-infected_JJ cells_NNS ._SENT |_SYM There_EX is_VBZ a_DT quantitative_JJ difference_NN in_IN steady-state_NN TbetaRII_NP mRNA_NN and_CC protein_NN levels_NNS in_IN infected_JJ cells_NNS :_: whereas_IN TbetaRII_NP protein_NN levels_NNS were_VBD decreased_VBN 10-fold_NN by_IN 19_CD h_NN p.i._NN ,_, there_EX was_VBD only_RB a_DT 2.4-_CD to_TO 2.7-fold_JJ decrease_NN in_IN steady-state_NN TbetaRII_NP mRNA_NP levels_NNS at_IN this_DT time_NN compared_VBN to_TO levels_NNS in_IN mock-infected_JJ cells_NNS ._SENT This_DT difference_NN was_VBD not_RB due_JJ to_TO the_DT host_NN cell_NN shutoff_NN that_WDT is_VBZ observed_VBN during_IN the_DT late_JJ stages_NNS of_IN infection_NN inasmuch_RB as_IN experiments_NNS were_VBD done_VBN under_IN conditions_NNS where_WRB infection_NN was_VBD limited_VBN to_TO the_DT early_JJ phase_NN ._SENT A_DT TbetaRII_NP protein_NN pulse-chase_NN experiment_NN was_VBD performed_VBN to_TO examine_VB potential_JJ differences_NNS in_IN the_DT rates_NNS of_IN synthesis_NN and_CC the_DT half-lives_NNS of_IN TbetaRII_NP in_IN adenovirus-_NN and_CC mock-infected_JJ cells_NNS ._SENT A549_NP cells_NNS were_VBD infected_VBN at_IN 50_CD PFU/cell_NP and_CC maintained_VBN in_IN freshly_RB supplied_VBN AraC_NP throughout_IN the_DT experiment_NN ._SENT At_IN 19_CD h_NN p.i._NN ,_, cells_NNS were_VBD metabolically_RB labeled_VBN with_IN a_DT [_SYM 35S]cysteine-methionine_JJ mixture_NN for_IN 15_CD min_NN and_CC chased_VBD in_IN cold_JJ medium_NN (_( Fig._NN and_CC D_NN )_) ._SENT TbetaRII_NP was_VBD immunoprecipitated_VBN ,_, resolved_VBN by_IN SDS-PAGE_NP ,_, and_CC detected_VBD by_IN a_DT STORM_NP phosphorimager_NN as_RB well_RB as_IN autoradiography_NN ._SENT The_DT phosphorimager_NN signal_NN was_VBD quantified_VBN with_IN ImageQuant_NP software_NN (_( Fig._NN and_CC E_NN )_) ._SENT Representative_NN autoradiograms_NNS and_CC phosphorimager_NN quantitations_NNS of_IN the_DT TbetaRII-specific_JJ signal_NN from_IN two_CD independent_JJ experiments_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Since_IN a_DT 2.4-_CD to_TO 2.7-fold_JJ decrease_NN in_IN TbetaRII_NP mRNA_NP was_VBD observed_VBN in_IN infected_JJ cells_NNS ,_, the_DT decrease_NN in_IN the_DT levels_NNS of_IN TbetaRII_NP protein_NN in_IN infected_JJ cells_NNS detected_VBN at_IN 0_CD min_NN of_IN chase_NN ,_, compared_VBN to_TO the_DT level_NN in_IN mock-infected_JJ cells_NNS ,_, should_MD not_RB be_VB more_JJR than_IN this_DT ,_, unless_IN the_DT translation_NN step_NN is_VBZ affected_VBN ._SENT TbetaRII_NP mRNA_NP possesses_VBZ extended_JJ 5_CD '_'' and_CC 3_CD '_'' untranslated_JJ regions_NNS ;_: therefore_RB ,_, translational_JJ regulation_NN of_IN TbetaRII_NP abundance_NN is_VBZ conceivable_JJ ._SENT In_IN multiple_JJ experiments_NNS (_( more_JJR than_IN five_CD )_) ,_, there_EX was_VBD approximately_RB a_DT twofold_JJ difference_NN in_IN the_DT TbetaRII_NP between_IN the_DT adenovirus-_NN and_CC mock-infected_JJ cells_NNS at_IN 0_CD min_NN of_IN chase_JJ (_( Fig._NN and_CC D_NP ;_: quantitation_NN in_IN Fig._NN and_CC E_NN )_) ;_: this_DT suggests_VBZ that_IN TbetaRII_NP translation_NN was_VBD not_RB markedly_RB affected_VBN by_IN adenovirus_NN infection_NN ._SENT Curiously_RB ,_, for_IN both_CC the_DT mock-infected_JJ and_CC infected_JJ samples_NNS ,_, there_EX was_VBD an_DT increase_NN in_IN detectable_JJ TbetaRII_NP following_VBG the_DT chase_NN ,_, peaking_VBG at_IN about_RB 30_CD min_NN of_IN chase_NN ._SENT This_DT increase_NN was_VBD reproducible_JJ and_CC was_VBD seen_VBN in_IN A549_NP and_CC HepG2_NP cells_NNS ._SENT Further_RBR ,_, it_PP occurred_VBD even_RB when_WRB the_DT chase_NN was_VBD conducted_VBN in_IN the_DT presence_NN of_IN cycloheximide_NN to_TO inhibit_VB the_DT elongation_NN of_IN translation_NN (_( data_NNS not_RB shown_VBN )_) ._SENT One_CD explanation_NN is_VBZ that_IN the_DT antibody_NN used_VBD does_VBZ not_RB efficiently_RB detect_VB the_DT initial_JJ form_NN of_IN TbetaRII_NP ;_: it_PP detects_VBZ only_RB a_DT form_NN that_WDT arises_VBZ from_IN posttranslational_JJ modifications_NNS ._SENT In_IN any_DT event_NN ,_, this_DT increase_NN in_IN detectable_JJ TbetaRII_NP was_VBD reproducibly_RB lower_JJR in_IN infected_JJ cells_NNS than_IN in_IN mock-infected_JJ cells_NNS ;_: this_DT is_VBZ apparent_JJ in_IN Fig._NN ,_, in_IN which_WDT the_DT curves_NNS for_IN the_DT infected_JJ and_CC mock-infected_JJ samples_NNS are_VBP superimposed_VBN ._SENT To_TO calculate_VB the_DT TbetaRII_NP half-life_NN ,_, data_NN points_NNS obtained_VBN for_IN both_DT mock-infected_JJ and_CC infected_JJ cells_NNS were_VBD fitted_VBN to_TO an_DT exponential_JJ equation_NN with_IN Excel_NP ._SENT The_DT fitness_NN of_IN the_DT exponential_JJ trend_NN was_VBD confirmed_VBN by_IN the_DT corresponding_JJ R2_NP values_NNS ._SENT Because_IN of_IN the_DT delay_NN in_IN peak_JJ accumulation_NN of_IN TbetaRII_NP ,_, only_JJ data_NN points_NNS taken_VBN from_IN the_DT 60-_CD to_TO 150-min_JJ chase_JJ interval_NN were_VBD used_VBN to_TO determine_VB the_DT TbetaRII_NP half-life_NN ._SENT A_DT TbetaRII_NP half-life_NN of_IN 40_CD min_NN in_IN mock-infected_JJ A549_NP cells_NNS was_VBD calculated_VBN ._SENT This_DT calculated_JJ half-life_NN is_VBZ shorter_JJR than_IN the_DT reported_JJ TbetaRII_NP half-life_NN of_IN 1.5_CD to_TO 2_CD h_NN in_IN mink_NN lung_NN epithelial_JJ cells_NNS ,_, which_WDT may_MD be_VB a_DT species_NN or_CC cell_NN line_NN phenomenon_NN ._SENT Importantly_RB ,_, no_DT significant_JJ difference_NN in_IN TbetaRII_NP half-life_NN between_IN the_DT mock-_NN and_CC adenovirus-infected_JJ cells_NNS was_VBD found_VBN ._SENT At_IN this_DT point_NN we_PP cannot_MD explain_VB why_WRB ,_, if_IN the_DT half-lives_NNS of_IN the_DT protein_NN in_IN mock-_NN and_CC adenovirus-infected_JJ cells_NNS are_VBP the_DT same_JJ and_CC the_DT rate_NN of_IN precursor_NN synthesis_NN is_VBZ decreased_VBN 2-fold_NN ,_, a_DT 3-fold_JJ decrease_NN in_IN TbetaRII_NP mRNA_NP produces_VBZ a_DT 10-fold_NN decrease_NN in_IN TbetaRII_NP protein_NN in_IN infected_JJ cells_NNS ,_, as_RB determined_VBN by_IN Western_NP blotting_VBG ._SENT We_PP have_VBP repeated_VBN pulse-chase_NN and_CC immunoprecipitation_NN of_IN TbetaRII_NP using_VBG two_CD additional_JJ antibodies_NNS raised_VBN against_IN the_DT N-terminal_JJ and_CC C-terminal_JJ sequences_NNS of_IN the_DT protein_NN ;_: results_NNS were_VBD similar_JJ to_TO those_DT presented_VBN in_IN the_DT Fig._NN ._SENT In_IN addition_NN ,_, we_PP have_VBP tried_VBN two_CD alternative_NN lysis_NN buffers_NNS :_: radioimmunoprecipitation_NN assay_NN buffer_NN (_( used_VBN in_IN a_DT study_NN by_IN Wells_NP et_FW al._FW to_TO immunoprecipitate_VB TbetaRII_NP from_IN mink_NN cells_NNS in_IN a_DT pulse-chase_NN experiment_NN )_) and_CC Laemmli_NP buffer_NN (_( containing_VBG 1_CD %_NN SDS_NP )_) ._SENT Both_DT methods_NNS of_IN lysing_VBG cells_NNS yielded_VBD results_NNS similar_JJ to_TO the_DT one_CD shown_VBN in_IN Fig._NN ._SENT The_DT events_NNS occurring_VBG during_IN the_DT initial_JJ TbetaRII_NP processing_NN in_IN the_DT infected_JJ cells_NNS that_WDT lead_VBP to_TO decreased_VBN peak_NN detection_NN of_IN TbetaRII_NP (_( as_RB shown_VBN in_IN Fig._NN and_CC D_NN )_) could_MD potentially_RB contribute_VB to_TO TbetaRII_NP downregulation_NN ._SENT TGF-beta1_JJ signaling_VBG in_IN adenovirus-infected_JJ cells_NNS is_VBZ inhibited_VBN ._SENT |_SYM Given_VBN that_IN TbetaRII_NP levels_NNS in_IN infected_JJ cells_NNS are_VBP decreased_VBN and_CC that_IN the_DT protein_NN required_VBN for_IN the_DT decrease_NN is_VBZ E1A_NP ,_, then_RB E1A_NP should_MD inhibit_VB TGF-beta1-induced_NP signaling_VBG ._SENT To_TO examine_VB this_DT prediction_NN ,_, we_PP used_VBD a_DT transient-transfection_NN system_NN in_IN which_WDT HepG2_NP cells_NNS were_VBD transfected_VBN with_IN p3TP-lux_NNS ,_, a_DT TGF-beta1-responsive_JJ reporter_NN plasmid_NN ,_, and_CC pCMV-betagal_JJ as_IN a_DT transfection_NN control_NN ._SENT HepG2_JJ cells_NNS were_VBD used_VBN because_IN they_PP had_VBD a_DT higher_JJR efficiency_NN of_IN transfection_NN than_IN A549_NP cells_NNS ._SENT Subsequently_RB ,_, cells_NNS were_VBD either_RB mock-infected_VBN or_CC infected_VBN with_IN the_DT wild-type_NN adenovirus_NN or_CC mutants_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, upon_IN treatment_NN of_IN mock-infected_JJ cells_NNS with_IN 1_CD or_CC 5_CD ng_NNS of_IN active_JJ human_JJ recombinant_JJ TGF-beta1/ml_NP ,_, a_DT robust_JJ activation_NN of_IN the_DT signaling_VBG pathway_NN occurred_VBD ,_, as_RB is_VBZ evident_JJ from_IN the_DT increased_VBN luciferase_NN activity_NN ._SENT In_IN contrast_NN ,_, very_RB little_JJ activation_NN of_IN the_DT TGF-beta1_JJ signaling_VBG pathway_NN occurred_VBN in_IN rec700-infected_JJ cells_NNS ,_, as_RB illustrated_VBN by_IN a_DT minimal_JJ increase_NN in_IN luciferase_NN production_NN ._SENT Adenovirus_NN mutants_NNS expressing_VBG only_RB the_DT 12S_JJ E1A_NP wild-type_NN or_CC mutant_JJ isoform_NN were_VBD analyzed_VBN for_IN TGF-beta1_NP signaling_VBG ._SENT Signaling_VBG was_VBD inhibited_VBN in_IN cells_NNS infected_VBN with_IN 12Swt_NP and_CC the_DT 12S_JJ mutant_NN deficient_JJ in_IN pRB_NN binding_VBG (_( 12S.928_JJ )_) ,_, but_CC not_RB in_IN cells_NNS infected_VBN with_IN the_DT mutant_NN harboring_VBG a_DT deletion_NN in_IN the_DT N_NP terminus_NN (_( 12S.2-36_JJ )_) ._SENT These_DT results_NNS are_VBP consistent_JJ with_IN results_NNS in_IN Fig._NN ,_, which_WDT showed_VBD that_DT TbetaRII_NP protein_NN levels_NNS were_VBD downregulated_VBN by_IN 12Swt_NP and_CC by_IN the_DT 12S.928_JJ mutant_NN but_CC not_RB by_IN the_DT 12S.2-36_JJ mutant_NN ._SENT As_IN a_DT further_JJR check_NN for_IN the_DT ability_NN of_IN E1A_NP to_TO block_VB TGF-beta1_JJ signaling_VBG ,_, we_PP cotransfected_VBD the_DT p3TP-lux_NN reporter_NN with_IN plasmids_NNS expressing_VBG the_DT 13S_JJ and_CC 12S_JJ forms_NNS of_IN E1A_NP ._SENT As_IN shown_VBN in_IN Fig._NN ,_, both_CC E1A_NP isoforms_NNS reduced_VBD TGF-beta-induced_JJ luciferase_NN synthesis_NN ,_, confirming_VBG a_DT role_NN for_IN E1A_NP in_IN inhibiting_VBG TGF-beta1_JJ signal_NN transduction_NN and_CC indicating_VBG that_IN E1A_NP can_MD suppress_VB TGF-beta1_NP signaling_VBG in_IN the_DT absence_NN of_IN other_JJ adenovirus_NN proteins_NNS ._SENT Finally_RB ,_, we_PP examined_VBD the_DT levels_NNS of_IN phosphorylated_JJ Smad_NP 2_CD in_IN cells_NNS infected_VBN with_IN rec700_NN ._SENT Levels_NNS of_IN phospho-Smad_NN 2_CD in_IN mock-infected_JJ cells_NNS increased_VBN upon_IN TGF-beta1_JJ treatment_NN ,_, as_RB determined_VBN by_IN Western_JJ analysis_NN using_VBG the_DT anti-phospho-Smad_NN 2_CD antibody_NN (_( Fig._NN ,_, lanes_NNS a_DT and_CC b_LS )_) ._SENT Little_JJ Smad_NP 2_CD phosphorylation_NN was_VBD induced_VBN in_IN rec700-infected_JJ cells_NNS at_IN 20_CD h_NN p.i._NN (_( Fig._NN ,_, lane_JJ d_NN )_) ,_, and_CC no_DT phosphorylated_JJ Smad_NP 2_CD was_VBD detected_VBN in_IN infected_JJ cells_NNS at_IN 24_CD h_NN p.i._NN (_( Fig._NN ,_, lane_JJ e_NN )_) ._SENT The_DT lack_NN of_IN TGF-beta1-inducible_NP Smad_NP 2_CD phosphorylation_NN in_IN infected_JJ cells_NNS suggests_VBZ that_IN TbetaRII_NP downregulation_NN by_IN adenovirus_NN contributes_VBZ to_TO the_DT loss_NN of_IN TGF-beta1_NP signaling_VBG observed_JJ in_IN infected_JJ cells_NNS ._SENT TGF-beta1_NP reduces_VBZ the_DT accumulation_NN of_IN adenovirus_NN late_JJ proteins_NNS and_CC virus_NN yields_NNS ._SENT |_SYM Large_JJ amounts_NNS of_IN structural_JJ proteins_NNS are_VBP produced_VBN during_IN the_DT late_JJ stage_NN of_IN infection_NN ,_, and_CC expression_NN is_VBZ dependent_JJ on_IN adenovirus_NN genome_NN replication_NN ._SENT Synthesis_NN of_IN late_JJ proteins_NNS is_VBZ followed_VBN by_IN virion_NN assembly_NN and_CC release_NN ._SENT Therefore_RB ,_, the_DT levels_NNS of_IN structural_JJ proteins_NNS in_IN infected_JJ cells_NNS can_MD be_VB used_VBN to_TO evaluate_VB progression_NN through_IN the_DT viral_JJ life_NN cycle_NN ._SENT To_TO determine_VB whether_IN TGF-beta1_JJ signaling_VBG has_VBZ an_DT effect_NN on_IN adenovirus_NN life_NN cycle_NN progression_NN ,_, the_DT accumulation_NN of_IN adenovirus_NN late_RB proteins_VBZ as_RB well_RB as_IN E1A_NP proteins_NNS in_IN TGF-beta1_JJ treated_VBN cells_NNS was_VBD examined_VBN ._SENT A549_NN cells_NNS undergo_VBP growth_NN arrest_NN ,_, but_CC not_RB apoptosis_NN ,_, upon_IN treatment_NN with_IN active_JJ TGF-beta1_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN our_PP$ experiments_NNS ,_, prior_RB to_TO infection_NN ,_, A549_NP cells_NNS were_VBD maintained_VBN in_IN 10_CD or_CC 0.2_CD %_NN FCS_NN or_CC 0.2_CD %_NN FCS_NN containing_VBG 5_CD ng_NNS of_IN active_JJ TGF-beta1/ml_NN for_IN 3_CD days_NNS ._SENT Cells_NNS were_VBD subsequently_RB infected_VBN at_IN 35_CD PFU/cell_NN with_IN wild-type_NN dl309_NN or_CC mutant_JJ E1A.2-36_NP or_CC E1A.81-120_NP adenoviruses_NNS ._SENT Infected_JJ cells_NNS were_VBD kept_VBN under_IN conditions_NNS identical_JJ to_TO the_DT pretreatment_NN environment_NN ._SENT At_IN 24_CD h_NN p.i._NN ,_, levels_NNS of_IN adenovirus_NN structural_JJ and_CC E1A_NP proteins_NNS were_VBD examined_VBN by_IN Western_JJ analysis_NN using_VBG anti-Ad5_NN and_CC anti-E1A_NN antibodies_NNS ,_, respectively_RB ._SENT The_DT relative_JJ abundances_NNS of_IN structural_JJ and_CC E1A_NP proteins_NNS were_VBD quantified_VBN by_IN densitometric_JJ analysis_NN ._SENT In_IN addition_NN ,_, the_DT ratio_NN of_IN signal_NN in_IN serum-starved_JJ cells_NNS to_TO that_DT in_IN TGF-beta1-treated_JJ cells_NNS was_VBD calculated_VBN for_IN structural_JJ and_CC E1A_NP proteins_NNS (_( Fig._NN and_CC B_NN ,_, ratios_NNS of_IN lanes_NNS b_NN to_TO c_NN ,_, e_NN to_TO f_NN ,_, and_CC h_NN to_TO i_NP ;_: summarized_VBD in_IN Fig._NN )_) ._SENT Serum_NN starvation_NN had_VBD a_DT negligible_JJ effect_NN on_IN the_DT levels_NNS of_IN structural_JJ proteins_NNS for_IN all_DT three_CD viruses_NNS tested_VBN (_( Fig._NN ,_, compare_VBP lanes_NNS a_DT and_CC b_NN ,_, d_NN and_CC e_NN ,_, and_CC g_NN and_CC h_NN )_) ._SENT However_RB ,_, the_DT levels_NNS of_IN structural_JJ proteins_NNS in_IN serum-starved_JJ cells_NNS maintained_VBN in_IN the_DT presence_NN of_IN TGF-beta1_NP were_VBD decreased_VBN (_( Fig._NN ,_, lanes_NNS c_NN ,_, f_LS ,_, and_CC i_NP )_) ._SENT This_DT negative_JJ effect_NN was_VBD more_RBR pronounced_VBN in_IN cells_NNS infected_VBN with_IN E1A.2-36_NP ,_, a_DT mutant_JJ (_( similar_JJ to_TO 12S.2-36_JJ )_) incapable_JJ of_IN downregulating_VBG TbetaRII_NP and_CC inhibiting_VBG TGF-beta1_JJ signaling_VBG ._SENT While_IN the_DT ratios_NNS of_IN the_DT amounts_NNS of_IN structural_JJ proteins_NNS in_IN serum-starved_JJ 